Trial Outcomes & Findings for A 3 Years Naturalistic Cohort Survey of Altis Single Incision Sling System For Female Stress Urinary Incontinence (NCT NCT04115605)
NCT ID: NCT04115605
Last Updated: 2026-05-26
Results Overview
Treatment success is a composite criterion defined in the protocol as condition improvement by Patient Global Impression of Improvement (PGI-I) reported as "a little better", "much better" or "very much better" and absence of serious or severe related Adverse Events (AEs) one year after implantation. As this definition of success was not restrictive enough, the Scientific Committee proposed a new definition for the treatment success for the statistical analysis, which was defined by PGI-I reported as "very much better" or "much better" and absence of any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs one year after implantation.
TERMINATED
598 participants
12 months
2026-05-26
Participant Flow
The first patient was included on 23rd May 2015. The last inclusion occurred on 21st September 2020.
598 subjects were enrolled but 34 subjects were excluded from analysis for the following reasons: 20 GCP compliance deviations, 13 screening failures and 1 implanted patient but whose procedure form was not captured in the eCRF.
Participant milestones
| Measure |
Intent-to-treat Population
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but no procedure form completed in eCRF
|
|---|---|
|
Overall Study
STARTED
|
564
|
|
Overall Study
2-month postoperative follow-up
|
545
|
|
Overall Study
1-year postoperative follow-up
|
427
|
|
Overall Study
2-year postoperative follow-up
|
362
|
|
Overall Study
3-year postoperative follow-up
|
307
|
|
Overall Study
COMPLETED
|
307
|
|
Overall Study
NOT COMPLETED
|
257
|
Reasons for withdrawal
| Measure |
Intent-to-treat Population
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but no procedure form completed in eCRF
|
|---|---|
|
Overall Study
Lost to Follow-up
|
207
|
|
Overall Study
Other reason
|
18
|
|
Overall Study
Withdrawal by Subject
|
16
|
|
Overall Study
Treatment failure
|
7
|
|
Overall Study
Adverse Event
|
4
|
|
Overall Study
Death
|
3
|
|
Overall Study
Implantation of another device
|
2
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but no procedure form completed in eCRF
|
|---|---|
|
Age, Continuous
|
51.5 Years
n=564 Participants
|
|
Body Mass Index
|
25.0 kg/m2
n=564 Participants
|
|
Duration since urinary incontinence onset
|
4.5 Years
n=564 Participants
|
|
Pure stress urinary incontinence
|
399 Participants
n=564 Participants
|
|
Sex: Female, Male
Female
|
564 Participants
n=564 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=564 Participants
|
PRIMARY outcome
Timeframe: 12 monthsPopulation: 400 patients completed the study questionnaires at one year post-implantation but 3 PGI-I data were missing
Treatment success is a composite criterion defined in the protocol as condition improvement by Patient Global Impression of Improvement (PGI-I) reported as "a little better", "much better" or "very much better" and absence of serious or severe related Adverse Events (AEs) one year after implantation. As this definition of success was not restrictive enough, the Scientific Committee proposed a new definition for the treatment success for the statistical analysis, which was defined by PGI-I reported as "very much better" or "much better" and absence of any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs one year after implantation.
Outcome measures
| Measure |
Intent-to-treat Population
n=397 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Treatment Success
Treatment success as defined in the protocol
|
375 Participants
|
|
Treatment Success
Treatment success as defined by the Scientific Committee
|
344 Participants
|
PRIMARY outcome
Timeframe: 12 monthsPopulation: The analyses were performed on the population with available data for PGI-I at 12 months post-implantation.
PGI-I is one of the two outcome measures of the composite primary endpoint. It is a validated question that collects the patients' impression of improvement after the surgery. Among this 7 point-scale ("very much better", "much better", "a little better", "no change", "a little worse", "much worse" and "very much worse"), the patients are asked to check the one number that describes how their urinay tract condition is now, compared with how it's was before the surgery. The percentage of patients who describes "very much better" or "much better" or "little better" and the percentage of patients who describes "very much better" or "much better" were measured.
Outcome measures
| Measure |
Intent-to-treat Population
n=397 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Patient Global Impression of Improvement (PGI-I)
"A little better" or "Much better" or "Very much better"
|
377 Participants
|
|
Patient Global Impression of Improvement (PGI-I)
"Much better" or "Very much better"
|
349 Participants
|
PRIMARY outcome
Timeframe: 12 monthsPopulation: The analyses were performed on the population with available data for PGI-I at 12 months post-implantation.
Related Adverse Events (AEs) are one of the two outcome measures of the composite primary endpoint. All AEs related or judged related to the procedure or the device were reported. The percentage of patients without any severe or serious related AEs and the percentage of patients without any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs were measured.
Outcome measures
| Measure |
Intent-to-treat Population
n=397 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Related Adverse Events
Without any severe or serious related AEs
|
395 Participants
|
|
Related Adverse Events
Without any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs
|
389 Participants
|
SECONDARY outcome
Timeframe: 8 weeks, 24, 36 monthsPopulation: Questionnaires from 522 patients were received and validated (scores and sub-scores were able to be calculated and dates were coherent with a follow-up visit at 8 weeks, 12, 24 or 36 months post-implatantion). The analyses were performed on the population with available data for PGI-I at the different study timepoints.
Treatment success is a composite criterion defined in the protocol as condition improvement by Patient Global Impression of Improvement (PGI-I) reported as "a little better", "much better" or "very much better" and absence of serious or severe related adverse events one year after implantation. As this definition of success was not restrictive enough, the Scientific Committee proposed a new definition for the treatment success for the statistical analysis, which was defined by PGI-I reported as "very much better" or "much better" and absence of any severe or serious or grade ≥ III of the Clavien-Dindo classification related adverse event one year after implantation.
Outcome measures
| Measure |
Intent-to-treat Population
n=522 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Treatment Success
Treatment success as defined in the protocol at 8 weeks post-implantation
|
365 Participants
|
|
Treatment Success
Treatment success as defined by the Scientific Committee at 8 weeks post-implantation
|
334 Participants
|
|
Treatment Success
Treatment success as defined in the protocol at 24 months post-implantation
|
318 Participants
|
|
Treatment Success
Treatment success as defined by the Scientific Committee at 24 months post-implantation
|
296 Participants
|
|
Treatment Success
Treatment success as defined in the protocol at 36 months post-implantation
|
273 Participants
|
|
Treatment Success
Treatment success as defined by the Scientific Committee at 36 months post-implantation
|
240 Participants
|
SECONDARY outcome
Timeframe: Baseline, 8 weeks and 12 monthsPopulation: The analyses were performed on the population with available data for CST (negative or postive result) at the different study timepoints.
CST provides the means for documenting stress urinary incontinence. CST is considered "positive" if any leakage is noted with cough or valsava. The percentage of patients with negative test was calculated at baseline, at the post-operative visit and at one year.
Outcome measures
| Measure |
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Cough Stress Test (CST)
Negative CST at baseline
|
39 Participants
|
|
Cough Stress Test (CST)
Negative CST at 8 weeks post-implantation
|
419 Participants
|
|
Cough Stress Test (CST)
Negative CST at 12 months post-implantation
|
276 Participants
|
SECONDARY outcome
Timeframe: Baseline, 8 weeks and 12 monthsPopulation: The analyses were performed on the population with available data for PVR at the different study timepoints. PVRs at 8 weeks and 12 months post-implantation were not interpretable because of too many missing data.
Post-void residual (PVR) volume was collected pre- and post implant procedure up to 12 months. If the PVR volume was considered normal by the physician after the procedure, it was not necessary to collect this data at the subsequent follow-up visits.
Outcome measures
| Measure |
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Post-void Residual (PVR) Volume
At baseline
|
0 mL
Inter-Quartile Range 28.8 • Interval 0.0 to 25.0
|
|
Post-void Residual (PVR) Volume
PVR at 8 weeks post-implantation
|
15 mL
Interval 0.0 to 35.0
|
|
Post-void Residual (PVR) Volume
PVR at 12 months post-implantation
|
15 mL
Interval 0.0 to 33.0
|
SECONDARY outcome
Timeframe: Baseline, 8 weeks, 12, 24 and 36 monthsPopulation: The analyses were performed on the population with available data for pad use at the different study timepoints. Data obtained either by follow-up or by questionnaires were pooled.
The number of pads used per patient per day was collected. Patients were considered to be pad free if they reported never wearing pads or wear pads just for a sense of security.
Outcome measures
| Measure |
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Pad Use
At baseline
|
2 number of pads used per patient per day
Inter-Quartile Range 1.9 • Interval 1.0 to 3.0
|
|
Pad Use
At 8 weeks post-implantation
|
0 number of pads used per patient per day
Inter-Quartile Range 1.1 • Interval 0.0 to 1.0
|
|
Pad Use
At 12 months post-implantation
|
0 number of pads used per patient per day
Inter-Quartile Range 1.1 • Interval 0.0 to 1.0
|
|
Pad Use
At 24 months post-implantation
|
0 number of pads used per patient per day
Inter-Quartile Range 1.3 • Interval 0.0 to 1.0
|
|
Pad Use
At 36 months post-implantation
|
0 number of pads used per patient per day
Inter-Quartile Range 1.0 • Interval 0.0 to 1.0
|
SECONDARY outcome
Timeframe: Baseline, 8 weeks, 12, 24 and 36 monthsPopulation: The analyses were performed on the population with available data for ICIQ-UI at the different study timepoints.
The ICIQ-UI Short Form is a seft-administred questionnaire to evaluate the frequency, severity and impact on quality of life of urinary incontinence. Question 1 asked, "How often do you leak urine?" Subjects were instructed to select among "none" (0), "about once a week or less often" (1), "2 or 3 times a week" (2), "about once a day" (3), "several times a day" (4), and "all the time" (5). Question 2 asked, "How much urine do you usually leak (whether you wear protection or not)?" Patients responded with "none" (0), "a small amount" (2), "a moderate amount" (4) or "a large amount (6). Question 3 asked, "Overall, how much does leaking urine interfere with your everyday life?" Participants chose a number from 0 (not at all) to 10 (a great deal). Question 1, 2 and 3 are summed to compute the total ICIQ score.The total score range is then a minimum of 0 to a maximum of 21.
Outcome measures
| Measure |
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At baseline
|
14 Score from 0 to 21
Interval 12.0 to 16.0
|
|
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 8 weeks post-implantation
|
0 Score from 0 to 21
Interval 0.0 to 5.0
|
|
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 12 months post-implantation
|
0 Score from 0 to 21
Interval 0.0 to 5.0
|
|
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 24 months post-implantation
|
1 Score from 0 to 21
Interval 0.0 to 6.0
|
|
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 36 months post-implantation
|
1 Score from 0 to 21
Interval 0.0 to 6.0
|
SECONDARY outcome
Timeframe: 8 weeks, 12, 24, 36 monthsPopulation: Questionnaires from 522 patients were received and validated (scores and sub-scores were able to be calculated and dates were coherent with a follow-up visit at 8 weeks, 12, 24 or 36 months post-implatantion). The analyses were performed on the population with available data for the Subject global statisfaction questionnaire at the different study timepoints.
This non-validated questionnaire provides additional information concerning patient satisfaction. This survey consists of two questions: Question 1 "how satisfied are you with your surgery?". Among 5 point-scale (very satisfied, satisfied, not satisfied-not dissatisfied, dissatisfied and very dissatified), patient check the one items that best describes the subject satisfaction. We measured the percentage of patients who were very satisfied and satisfied. The patients answer the question "Do you recommend this operation to a friend?" by "yes" or "no". We measured the percentage of patients who answered "yes".
Outcome measures
| Measure |
Intent-to-treat Population
n=522 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 8 weeks
|
93.1 Percentage of patients
Interval 91.8 to 94.4
|
|
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 8 weeks
|
97.1 Percentage of patients
Interval 95.4 to 98.8
|
|
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 12 months
|
90.4 Percentage of patients
Interval 87.5 to 93.3
|
|
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 12 months
|
97.2 Percentage of patients
Interval 95.6 to 98.8
|
|
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 24 months
|
91.4 Percentage of patients
Interval 88.3 to 94.5
|
|
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 24 months
|
95.8 Percentage of patients
Interval 93.6 to 98.0
|
|
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 36 months
|
89.9 Percentage of patients
Interval 86.6 to 93.5
|
|
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 36 months
|
94.5 Percentage of patients
Interval 91.9 to 97.1
|
SECONDARY outcome
Timeframe: Baseline, 8 weeks, 12, 24, 36 monthsPopulation: The analyses were performed on the population with available data for I-QoL at the different study timepoints.
The Incontinence quality of life questionnaire (I-QoL) is a validated survey questionnaire with 22 items that are scored on a 5-point Likert scale. The I-QOL and its subcale scores are computed by adding each item response, subtracting the lowest possible score and diving that sum by the possible raw score range. The scores are then transformed to have a range from 0 (maximum problem) to 100 (no problem at all).
Outcome measures
| Measure |
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Incontinence Quality of Life Questionnaire (I-QoL)
At 36 months post-implantation
|
94.8 Score from 0 to 100
Interval 87.5 to 100.0
|
|
Incontinence Quality of Life Questionnaire (I-QoL)
At baseline
|
53.4 Score from 0 to 100
Interval 37.8 to 71.6
|
|
Incontinence Quality of Life Questionnaire (I-QoL)
At 8 weeks post-implantation
|
93.2 Score from 0 to 100
Interval 83.0 to 98.8
|
|
Incontinence Quality of Life Questionnaire (I-QoL)
At 12 months post-implantation
|
95.5 Score from 0 to 100
Interval 88.6 to 98.9
|
|
Incontinence Quality of Life Questionnaire (I-QoL)
At 24 months post-implantation
|
95.5 Score from 0 to 100
Interval 88.6 to 98.9
|
SECONDARY outcome
Timeframe: Baseline, 8 weeks, 12, 24, 36 monthsPopulation: The analyses were performed on the population with available data for PISQ-12 at the different study timepoints.
The Pelvic organ/urinary incontinence sexual questionnaire (PISQ-12) is a validated and reliable short form questionnaire including 12 questions that evaluates sexual function in heterosexual women with urinary incontinence and/or pelvic organ prolapse. Reponses are graded on a 5-point Likert scale from "never" to "always". The scores were calculated at each assessment visit.
Outcome measures
| Measure |
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At baseline
|
35 Score from 5 to 60
Interval 30.0 to 40.0
|
|
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 8 weeks post-implantation
|
37 Score from 5 to 60
Interval 33.0 to 41.0
|
|
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 12 months post-implantation
|
38 Score from 5 to 60
Interval 33.0 to 41.0
|
|
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 24 months post-implantation
|
38.0 Score from 5 to 60
Interval 33.8 to 42.0
|
|
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 36 months post-implantation
|
38.0 Score from 5 to 60
Interval 31.6 to 42.0
|
SECONDARY outcome
Timeframe: 8 weeks, 24, 36 monthsPopulation: Questionnaires from 522 patients were received and validated (scores and sub-scores were able to be calculated and dates were coherent with a follow-up visit at 8 weeks, 12, 24 or 36 months post-implatantion). The analyses were performed on the population with available data for PGI-I at the different study timepoints.
PGI-I is a validated question that collects the patients' impression of improvement after the surgery. Among this 7 point-scale ("very much better", "much better", "a little better", "no change", "a little worse", "much worse" and "very much worse"), the patients are asked to check the one number that describes how their urinay tract condition is now, compared with how it's was before the surgery. The percentage of patients who describes "very much better" or "much better" or "little better" was measured.
Outcome measures
| Measure |
Intent-to-treat Population
n=522 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Patient Global Impression of Improvement (PGI-I)
At 8 weeks post-implantation
|
371 Participants
|
|
Patient Global Impression of Improvement (PGI-I)
At 24 months post-implantation
|
321 Participants
|
|
Patient Global Impression of Improvement (PGI-I)
At 36 months post-implantation
|
277 Participants
|
Adverse Events
Intent-to-treat Population
Serious adverse events
| Measure |
Intent-to-treat Population
n=564 participants at risk
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
General disorders
Vaginal mesh exposure
|
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Product Issues
Urethral mesh extrusion
|
0.35%
2/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
Other adverse events
| Measure |
Intent-to-treat Population
n=564 participants at risk
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
|
|---|---|
|
Injury, poisoning and procedural complications
Bladder Perforation
|
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Reproductive system and breast disorders
Dyspareunia
|
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Renal and urinary disorders
Dysuria
|
2.0%
11/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Musculoskeletal and connective tissue disorders
Non-Urogenital Pain
|
10.6%
60/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Injury, poisoning and procedural complications
Paresthesia
|
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Renal and urinary disorders
Pollakiuria
|
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Injury, poisoning and procedural complications
Post-procedural Haematoma
|
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Renal and urinary disorders
Slow Stream
|
0.35%
2/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Reproductive system and breast disorders
Synechiae
|
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Renal and urinary disorders
Urgency
|
1.4%
8/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Renal and urinary disorders
Urgency Urinary Incontinence
|
1.2%
7/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Renal and urinary disorders
Urinary Retention
|
5.0%
28/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Renal and urinary disorders
Urinary Tract Infection
|
2.0%
11/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Reproductive system and breast disorders
Urogenital Pain
|
0.71%
4/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
General disorders
Vaginal Mesh Exposure
|
1.1%
6/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
Injury, poisoning and procedural complications
Vaginal Perforation
|
0.35%
2/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
|
General disorders
Vaginal Thread Exposure
|
0.53%
3/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
|
Additional Information
Mrs Martine Dehez, Manager, Clinical Quality & EU Clinical Research
Coloplast Manufacturing France
Results disclosure agreements
- Principal investigator is a sponsor employee By signing the study agreement, the investigators have undertaken to keep confidential and not to disclose to any third party without the prior formal written consent of the sponsor any data relating to the study, its results, and its follow-up that is not in the public domain.
- Publication restrictions are in place
Restriction type: OTHER